FDA to Rule on Sarepta's Duchenne Gene Therapy Today

Sarepta Therapeutics is awaiting FDA approval for its gene therapy for Duchenne muscular dystrophy, with the decision expected to be announced today. The approval is likely to be limited to boys aged 4 and 5 years old, rather than the broader subset of patients originally studied in trials. The therapy, SRP-9001, is a one-time gene therapy for young boys with the debilitating muscle disease.